Aggressive Antibiotics in Palliative Care: Pneumonia Outcomes Defy Expectations in Acute Units

Pneumonia in patients with advanced cancer has long been treated as a fork in the road: either escalate toward intensive antimicrobial therapy and diagnostic work-ups, or pivot fully toward comfort and symptom control. A new retrospective observational study from an acute palliative care unit (APCU) in Italy suggests that this dichotomy may be false. Published in Supportive Care in Cancer, the study by Sebastiano Mercadante and colleagues at La Maddalena Cancer Center in Palermo documents a year of consecutive admissions in which pneumonia was diagnosed, treated aggressively, and, in the majority of cases, resolved well enough for patients to leave the unit alive and return to home or community-based palliative care.

The numbers behind the study are straightforward but telling. Over a one-year period in 2024, the unit recorded 550 admissions. Twenty-two of those patients, or 4.0 percent, received a diagnosis of pneumonia. That figure may appear modest, but it captures a population whose clinical fragility is extreme: the mean Karnofsky Performance Status, a standard 0-to-100 scale of functional ability, was 44.1, meaning the average patient required substantial assistance with daily activities and spent much of the time resting or in bed. In oncology practice, a KPS in the forties signals a body with limited physiological reserve, where even a localized lung infection can rapidly destabilize multiple organ systems.

What distinguishes this cohort is the diagnostic intensity applied. Every one of the 22 patients underwent computed tomography of the chest to establish the diagnosis. In many palliative settings, imaging beyond a portable chest radiograph is often considered unnecessary or burdensome, particularly when the therapeutic plan would not change. The Palermo team’s decision to obtain CT scans across the board reflects the philosophy of the APCU model: these units are designed to handle acute complications of advanced disease with the same diagnostic rigor as an oncology ward, while keeping the goals of care anchored in symptom relief and rapid stabilization rather than curative pursuit.

Therapeutically, the approach was equally assertive. All patients received antibiotic therapy, and the agents selected were predominantly broad-spectrum intravenous drugs used for hospital-acquired and complicated pneumonias. Piperacillin combined with the beta-lactamase inhibitor tazobactam was the most frequent choice, given to 54.5 percent of the cohort, while the carbapenem meropenem was used in 36.4 percent. These are not marginal drugs; they are workhorses of empirical therapy for serious gram-negative infections, chosen when resistance risk is high or when the clinical picture leaves little room for narrow-spectrum trial and error. The pattern suggests that the treating clinicians regarded these infections as genuine threats requiring potent coverage, not as terminal events to be managed with placebo or minimal intervention.

The outcomes lend weight to that judgment. Among evaluable cases, clinical resolution of the infection was achieved in 80 percent. More striking still, 72.7 percent of the patients were discharged successfully, either to their homes or to community-based palliative care services, and the mortality rate within the APCU itself was 9.1 percent. For a population with a mean KPS of 44 and active pneumonia, those figures challenge the assumption that infection in advanced cancer is an inevitable terminal milestone. Instead, the data support the idea that timely, intensive antimicrobial treatment can buy patients the time and stability needed to return to their preferred care settings, which for most people means being at home.

Symptom trajectories add an important nuance. Dyspnea, the subjective sensation of breathlessness that often accompanies pneumonia, was measured at admission using the Edmonton Symptom Assessment System, a validated patient-reported tool. The mean ESAS dyspnea score was 3.21, with a standard deviation of 2.35, indicating moderate breathlessness on average but with wide variability across patients. Notably, when the researchers compared dyspnea scores at the time of clinical resolution and at discharge against the admission values, they found no statistically significant change, with a p-value of 0.396. In other words, treating the infection did not dramatically worsen or improve the reported breathlessness, a finding that underscores how multifactorial dyspnea is in advanced cancer, where causes such as pleural disease, anemia, muscle weakness, and anxiety frequently coexist with infection.

Oxygen requirements followed a similar pattern of partial stabilization. At admission, 31.8 percent of the patients needed supplemental oxygen. By the time of discharge, that proportion had fallen only slightly, to 27.3 percent. The modest decline suggests that while antimicrobial therapy and supportive care allowed most patients to leave the unit, the underlying respiratory compromise often persisted, consistent with the limited pulmonary reserve typical of this population. For clinicians, the implication is that antibiotic success in this setting should be judged primarily by infection control and functional stabilization rather than by complete normalization of breathing or oxygen needs.

The study sits within a broader and sometimes contentious literature on antimicrobial use at the end of life. Prior research has documented that a large share of hospice and palliative patients receive antibiotics in their final days, raising questions about whether such treatment prolongs suffering, contributes to resistance, or merely delays an inevitable decline. Some studies have found that antibiotics can relieve infection-related symptoms, while others question whether withdrawal of antimicrobials in terminal patients is appropriate or harmful. The Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America have published stewardship guidelines that apply to all clinical settings, yet their implementation in palliative contexts remains uneven and ethically fraught. The Palermo data do not resolve these debates, but they do demonstrate that in a specialized acute unit, high-intensity treatment and palliative goals can coexist without the one negating the other.

The APCU model itself is central to interpreting the findings. Acute palliative care units, often embedded within comprehensive cancer centers, are designed for rapid assessment and short-stay management of severe complications such as uncontrolled pain, delirium, bleeding, and infections. Reviews led by some of the same authors have argued that such units should be considered mandatory infrastructure for cancer centers and tertiary hospitals, precisely because they bridge the gap between the ward, where curative or life-prolonging priorities dominate, and hospice, where the focus shifts entirely to comfort. The present study illustrates that bridge in action: patients arrived acutely ill, received CT-based diagnosis and broad-spectrum antibiotics, and most were stabilized and discharged within the unit’s rapid-cycle framework.

Several caveats temper the conclusions. The study is retrospective and single-center, drawing on 22 patients over one year, so the findings may not generalize to units with different staffing, patient mixes, or antimicrobial policies. The abstract does not report microbiological culture results, which limits insight into whether the chosen broad-spectrum regimens matched the actual pathogens. Nor does it detail long-term survival after discharge, an outcome that matters greatly when weighing the burdens of intensive treatment against its benefits. Nonetheless, the core message is clear and clinically useful: in an acute palliative care unit equipped for high diagnostic and therapeutic intensity, pneumonia in advanced cancer is frequently treatable, and treating it does not conflict with palliative intent. For the four in five patients whose infections resolved and the nearly three in four who went home, the aggressive approach translated into time in the place they most wanted to be.

Subject of Research: Prevalence, management, and outcomes of pneumonia among patients admitted to an acute palliative care unit for advanced cancer

Article Title: Pulmonary infections in an acute palliative care unit

Article References: Mercadante, S., Settepani, S., Grassi, Y., Mancuso, G., & Cascio, A. L. (2026). Pulmonary infections in an acute palliative care unit. Supportive Care in Cancer, 34(10), Article 969. https://doi.org/10.1007/s00520-026-11067-1

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11067-1

Keywords: pneumonia, palliative care, acute palliative care unit, advanced cancer, antibiotics, piperacillin-tazobactam, meropenem, dyspnea, Karnofsky Performance Status, supportive care, antimicrobial stewardship, cancer center